Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026

Caribou Biosciences, Inc.

Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.
Discontinues allogeneic CAR-NK preclinical research; focuses on CAR-T cell therapy and four clinical programs.
Workforce reduction of 21 positions (~12%); expects to complete by end of Q3 2024.
Estimated severance costs $0.5M–$1.0M in Q3 2024.
Cash runway extended at least 6 months into H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.